Skip to Content

Altimmune to Participate in the 10th Annual Biotech Showcase in San Francisco, January 8 – 10, 2018

Dec 21, 2017

GAITHERSBURG, Md., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at the 10th Annual Biotech Showcase, being held January 8-10, 2018 at the Hilton San Francisco Union Square in San Francisco, California.

 
10th Annual Biotech Showcase Presentation Details
Date:   Monday, January 8, 2018
Time:   10:00am Pacific Time
Location:   Hilton San Francisco Union Square, Franciscan A Ballroom
Webcast:   https://event.webcasts.com/starthere.jsp?ei=1176122&tp_key=878f421c1b 
     

Altimmune will also be hosting institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

To schedule a meeting with Altimmune, investors can register on the online system managed by the Company’s US investor relations firm, LifeSci Advisors, LLC, or make a request via e-mail at Access@LifeSciAdvisors.com.

About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
Email: enright@altimmune.com

Ashley Robinson
Managing Director LifeSci Advisors
Phone: 617-535-7742
Email: arr@lifesciadvisors.com

Primary Logo

 

Source: Altimmune, Inc.